Senseonics Eversense 365 Receives FDA Approval as World’s First Year-Long Wearable CGM, Expanded Medicare Coverage to Reshape Market

August 17, 2026

Constancy Researchers America

Overview

Senseonics’ Eversense 365 has secured FDA approval, becoming the world’s first commercially available year-long implantable continuous glucose monitor (CGM). This innovation fundamentally improves patient quality of life by eliminating the stress of frequent sensor changes and warm-up periods. Furthermore, expanded Medicare coverage for Type 2 non-insulin using patients in 2026, combined with accelerated OTC approvals, significantly broadens the addressable market for CGMs. This groundbreaking product enhances the convenience and sustainability of diabetes management.

In Depth

Key Findings

Senseonics Holdings’ Eversense 365 has received U.S. Food and Drug Administration (FDA) approval, marking its entry into the market as the world’s first commercially available year-long implantable continuous glucose monitoring (CGM) system. This groundbreaking device is designed to fundamentally improve the quality of life for individuals with diabetes by significantly reducing the stress associated with frequent sensor replacements and their accompanying warm-up periods. Additionally, expanded Medicare coverage for Type 2 non-insulin using patients in 2026 has boosted overall CGM accessibility, including for Eversense 365, dramatically expanding the addressable market.

Technical/Clinical Details

The Eversense 365 system consists of a small sensor implanted subcutaneously in the upper arm, a removable smart transmitter worn on the skin surface, and a mobile app. This sensor continuously measures glucose levels for an entire year, transmitting real-time data to a smartphone via the smart transmitter. Patients only need to undergo a sensor replacement procedure once a year, eliminating the multiple-day warm-up periods seen in conventional CGMs. This ensures continuous data collection, enabling more stable insights into glucose trends. FDA approval signifies that Eversense 365 meets stringent clinical standards for safety and effectiveness, with its advantages in long-term adherence and patient convenience being particularly recognized. The expanded Medicare coverage opens pathways for Type 2 non-insulin using patients, who previously faced significant cost barriers, to access this advanced technology, thereby contributing to improved clinical outcomes.

Background & Context

The continuous glucose monitoring market plays a critical role in enhancing diabetes management, but sensor wear duration and replacement frequency have often posed barriers for patients. Senseonics Eversense 365’s year-long wear capability fundamentally addresses this issue, improving the sustainability and acceptance of CGM technology. The FDA approval and expanded Medicare coverage indicate that CGM technology is gaining broader acceptance within the U.S. diabetes care system and is becoming established as a standard of care. Particularly, the expansion to Type 2 non-insulin using patients holds significant implications from a preventive care and early intervention perspective, meaning more individuals, including those with pre-diabetes, can benefit from CGM.

Strategic Significance & Outlook

The market introduction of Senseonics Eversense 365 is a milestone in the evolution of CGM technology and a critical factor in shaping the future of diabetes management. A year-long wearable CGM will improve patient compliance and enable more effective treatment planning based on continuous data. The success of this technology is likely to encourage other companies to develop long-wear devices, accelerating innovation across the entire CGM market. Furthermore, the trend of expanded Medicare coverage and OTC approvals clearly indicates that CGM is transitioning from a specialized medical device to an everyday health management tool, with Senseonics at the forefront of this paradigm shift. In the future, the vast amounts of data collected from these long-wear devices are expected to integrate with AI, further contributing to personalized preventive care and treatment optimization.

Source: https://constancyresearchers.com/diabetes-care-devices-in-2026-dexcom-stelo-is-otc-abbott-has-the-first-dual-glucose-ketone-sensor-and-the-omnipod-5-is-about-to-pair-with-libre-3-plus/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.